An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys® and Viread® and REP 2165-Mg in Combination With Pegasys® and Viread® in Patients With HBeAg Negative Chronic Hepatitis B

Trial Profile

An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys® and Viread® and REP 2165-Mg in Combination With Pegasys® and Viread® in Patients With HBeAg Negative Chronic Hepatitis B

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs REP 2139-Ca (Primary) ; Interferon alpha-2a; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors REPLICor
  • Most Recent Events

    • 20 Apr 2017 Results published in a Replicor media release.
    • 20 Apr 2017 According to a Replicor media release, results from this trial were presented at the European Association for the Study of the Liver (EASL) 2017 annual meeting.
    • 20 Feb 2017 According to a Replicor media release, an updated interim analysis from this trial was presented at the Asia Pacific Association for the Study of Liver (APASL) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top